arrow
L

Lukasz P. Gondek

Johns Hopkins University
H指数:31
被引数:3,454

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms

CALR突变骨髓增殖性肿瘤的结局异质性

2026-10-070
PRE
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation

使用第二代酪氨酸激酶抑制剂的化疗方案治疗BCR-ABL B细胞急性淋巴细胞白血病的比较结果及异基因造血细胞移植的作用

2026-02-010
PRE
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53

Naji, N.S.; Pasca, S.; Chatzilygeroudi, T.; Toledano-Sanz, P.; Rimando, J.; An, Y.; Hemani, Y.; Perkins, B.; Zeng, X.; Talbot, C.; 等. C-C基序趋化因子受体样2促进具有红系分化和TP53突变髓系肿瘤的干扰素-γ信号反应。Haematologica, 2025. [Google Scholar] [CrossRef]

2026-02-013
OA
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

DDX41突变髓系肿瘤挑战现有的预后方案,并需要专门的危险评分系统:一项多中心、回顾性研究

Leukemia
IF13.4
2025-12-030
PRE
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
2025-11-011
OA
Efficacy and safety of blinatumomab for CD19+acute leukemias in patients historically excluded from clinical trials due to comorbidities

Blinatumomab对由于合并症而被历史性地排除在临床试验之外的CD19+急性白血病患者中的有效性和安全性

2025-09-010
OAAI
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes

从前列腺癌患者肿瘤DNA测序中推断出的克隆性造血:与肿瘤体细胞改变及预后的相关性

2025-04-220
OA
Deleterious heteroplasmic mitochondrial mutations are associated with an increased risk of overall and cancer-specific mortality
2023-09-309
OAAI
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
2023-07-065
OAAI